idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
10/22/2021 20:00

Mechanism Behind Ineffective Psoriasis Drugs Identified

Kurt Bodenmüller Kommunikation
Universität Zürich

    Interleukin-12 – a messenger molecule of immune cells – was long considered to trigger the development of psoriasis. Now, researchers at the University of Zurich have shown that interleukin-12 does not actually cause the skin disease but protects against it. This also explains why common psoriasis drugs that block the messenger show insufficient treatment efficacy.

    Interleukin-12 – a messenger molecule of immune cells – was long considered to trigger the development of psoriasis. Now, researchers at the University of Zurich have shown that interleukin-12 does not actually cause the skin disease but protects against it. This also explains why common psoriasis drugs that block the messenger show insufficient treatment efficacy.

    Psoriasis is a chronic inflammatory autoimmune disease that manifests as red, scaly skin patches. There is no causal treatment for the disease, but the symptoms can be significantly alleviated with modern therapies. Complex changes in the networks of immune cells and the messengers they use to communicate with each other are responsible for the development of the skin disease. Clinical trials revealed that newly developed drugs blocking only the messenger interleukin-23 are more effective than previous treatments targeting both interleukin-23 and interleukin-12 in psoriasis patients. The responsible mechanism has so far remained unknown. Now, researchers at the University of Zurich (UZH) have uncovered the underlying molecular mechanisms.

    Role of interleukin-12 in psoriasis decoded

    The research teams of immunology professor Burkhard Becher and group leader Sarah Mundt from the Institute of Experimental Immunology at UZH have systematically investigated the function of interleukin-12 in psoriasis. They show that the messenger does not contribute to the disease – on the contrary, it protects against it. "These results surprised us, because so far drugs for the treatment of psoriasis also aim at blocking interleukin-12," says Becher.

    Interleukin-12 maintains normal function of skin cells

    Detailed studies in mice and with human tissue now show that various cell types in the skin are also equipped with receptors for interleukin-12. Not only the T cells of the immune system, but also keratinocytes, horn-forming skin cells that build up the epidermis, can thus recognize the messenger. In fact, the recognition of interleukin-12 by these skin cells was responsible for the protective effect of the messenger, as the researchers found out. "Interleukin-12 is essential for the normal, physiological function of keratinocytes. For example, it prevents the increased cell division observed in psoriasis," explains Mundt.

    Improving psoriasis treatment

    "Our findings indicate that blocking interleukin-12 is not advisable, and such drugs should therefore no longer be used to treat psoriasis patients," says Pascale Zwicky, PhD student and first author of the study. Accordingly, psoriasis drugs should only block the messenger substance interleukin-23, but no longer interleukin-23 and -12 together.

    The UZH researchers' findings could be important for the treatment of other diseases. "The combined blocking of interleukin-23 and -12 is also used in the treatment of chronic inflammatory bowel diseases and psoriatic arthritis," says Burkhard Becher. "In these diseases, the role of interleukin-12 has not yet been sufficiently studied. But here, too, a protective role of the messenger substance is possible."


    Contact for scientific information:

    Prof. Dr. Burkhard Becher
    Institute of Experimental Immunology
    University of Zurich
    Phone: +41 44 635 37 03
    E-mail: becher@immunology.uzh.ch

    Dr. Sarah Mundt
    Institute of Experimental Immunology
    University of Zurich
    Phone: +41 44 635 37 27
    E-mail: mundt@immunology.uzh.ch


    Original publication:

    Pascale Zwicky, Florian Ingelfinger, Bruno Marcel Silva de Melo, et. al. IL-12 regulates type 3 immunity through interfollicular keratinocytes in psoriasiform inflammation. Science Immunology. 20 October 2021. DOI: 10.1126/sciimmunol.abg9012


    More information:

    https://www.media.uzh.ch/en/Press-Releases/2021/Psoriasis.html


    Images

    In inflamed skin keratinocytes with the receptor for interleukin-12 (left) divide less than keratinocytes without this receptor (right). Red: cells during division, blue: cell nuclei, white line: epidermis.
    In inflamed skin keratinocytes with the receptor for interleukin-12 (left) divide less than keratino ...

    UZH


    Criteria of this press release:
    Journalists
    Biology, Medicine
    transregional, national
    Research results, Scientific Publications
    English


     

    In inflamed skin keratinocytes with the receptor for interleukin-12 (left) divide less than keratinocytes without this receptor (right). Red: cells during division, blue: cell nuclei, white line: epidermis.


    For download

    x

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).